%	O
%	O
TITLE	O

Impact	O
of	O
HPV	O
infection	O
on	O
gene	O
expression	O
and	O
methylation	O
in	O
oral	O
cancer	O
patients	O
.	O

%	O
%	O
ABSTRACT	O

The	O
current	O
study	O
aimed	O
to	O
examine	O
the	O
association	O
between	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(	O
HNSCC	O
)	O
and	O
infection	O
with	O
different	O
human	O
papillomavirus	O
virus	O
(	O
HPV	O
)	O
subtypes	O
,	O
including	O
analysis	O
of	O
promoter	O
methylation	O
of	O
several	O
genes	O
(	O
APC	O
,	O
CDKN2A	O
,	O
MGMT	O
,	O
CDH1	O
and	O
TIMP3	O
)	O
and	O
the	O
correlation	O
with	O
their	O
mRNA	O
expression	O
in	O
tumours	O
and	O
surgical	O
margins	O
.	O
In	O
47	B-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
a	I-Study_Cohort
primary	I-Study_Cohort
tumour	I-Study_Cohort
of	I-Study_Cohort
the	I-Study_Cohort
oral	I-Study_Cohort
cavity	I-Study_Cohort
,	O
HPV	O
detection	O
and	O
identification	O
of	O
33	O
subtypes	O
was	O
performed	O
after	O
previous	O
DNA	O
isolation	O
using	O

a	O
GenoFlow	O
HPV	O
Array	O
Test	O
Kit	O
.	O
Fifteen	O
patients	O
(	O
31	O
.	O
92â€Š	O
%	O
)	O
were	O
HPV	O
[	O
+	O
]	O
and	O
the	O
following	O
HPV	O
types	O
were	O
detected	O
:	O
16	O
(	O
46	O
.	O
67â€Š	O
%	O
)	O
,	O
18	O
(	O
6	O
.	O
67â€Š	O
%	O
)	O
and	O
43	O
/	O
44	O
(	O
40â€Š	O
%	O
)	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
describe	O
HPV	O
43	O
/	O
44	O
subtypes	O
in	O
HNSCC	O
in	O
a	O
Polish	O
population	O
.	O

We	O
noted	O
no	O
clinical	O
significance	O
of	O
HPV	O
[	O
+	O
]	O
HNSCC	O
compared	O
to	O
HPV	O
[	O
-	O
]	O
,	O
however	O
,	O
this	O
differed	O
among	O
HPV	O
subtypes	O
.	O

CDKN2A	O
promoter	O
methylation	O
was	O
more	O
frequent	O
in	O
HPV	O
-	O
16	O
/	O
18	O
patients	O
compared	O
to	O
HPV43	O
/	O
44	O
patients	O
,	O
but	O
there	O
was	O
no	O
difference	O
in	O
gene	O
expression	O
level	O
between	O
HPV	O
[	O
+	O
]	O
and	O
[	O
-	O
]	O
patients	O
.	O
We	O
detected	O
HPV	O
infection	O
in	O
31	O
.	O
92â€Š	O
%	O
of	O
oral	O
cancer	O
cases	O
.	O

HPV	O
16	O
,	O
along	O
with	O
HPV	O
43	O
/	O
44	O
,	O
were	O
the	O
most	O
frequent	O
subtypes	O
.	O

Knowledge	O
of	O
HPV	O
[	O
+	O
]	O
HNSCC	O
biology	O
may	O
be	O
useful	O
in	O
establishing	O
the	O
prognosis	O
and	O
developing	O
novel	O
therapies	O
in	O
future	O
.	O

%	O
%	O
METHODS	O

Study	O
population	O

This	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
on	O
Medical	O
Ethics	O
of	O
the	O
Maria	O
Skłodowska–Curie	O
Memo	O
-	O
rial	O
Cancer	O
Center	O
and	O
Institute	O
of	O
Oncology	O
in	O
Gliwice	O
(	O
No	O
KB	O
/	O
493	O
-	O
15	O
/	O
08	O
and	O
KB	O
/	O
430	O
-	O
47	O
/	O
13	O
)	O
.	O

From	O
all	O
patients	O
we	O
obtained	O
a	O
written	O
informed	O
consent	O
form	O
.	O

We	O
studied	O
47	B-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
a	I-Study_Cohort
primary	I-Study_Cohort
tumour	I-Study_Cohort
and	O
whose	O
clinical	O
charac	O
-	O
teristics	O
are	O
presented	O
in	O
.	O

All	O
tumours	O
collected	O
dur	O
-	O
ing	O
surgical	O
operations	O
were	O
classified	O
as	O
oral	O
cavity	O
cancers	O
,	O
including	O
those	O
involving	O
the	O
mandible	O
,	O
floor	O
of	O
the	O
mouth	O
,	O
tongue	O
and	O
cheek	O
.	O

Tumour	O
staging	O
was	O
determined	O
in	O
accordance	O
with	O
the	O
TNM	O
classification	O
[	O
]	O
.	O

Smoking	O
and	O
alcohol	O
information	O
was	O
obtained	O
from	O
patients’	O
medical	O
history	O
.	O

None	O
of	O
patients	O
had	O
received	O
preoperative	O
radio	O
-	O
or	O
chemotherapy	O
.	O

Patient	O
survival	O
rates	O
were	O
62	O
.	O
00	O
%	O
in	O
stage	O
>	O
II	O
TNM	O
and	O
100	O
%	O
in	O
stages	O
I	O
and	O
II	O
TNM	O
.	O

DNA	O
extraction	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
each	O
sample	B-HPV_Sample_Type
of	O
fresh	O
fro	O
-	O
zen	O
tumour	O
tissue	B-HPV_Sample_Type
(	O
20	O
mg	O
)	O
using	O
the	O
DNeasy	O
Blood	O
&	O
Tissue	O
Kit	O
(	O
Qiagen	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer’s	O

Table	O
1	O
.	O

Clinical	O
characteristics	O
of	O
patients	O

instructions	O
,	O
following	O
homogenization	O
of	O
tissues	B-HPV_Sample_Type
using	O
the	O
FastPrep	O
-	O
24	O
instrument	O
and	O
Lysing	O
Matrix	O
A	O
tubes	O
(	O
MP	O
Biomedicals	O
,	O
USA	O
)	O
.	O

Qualitative	O
and	O
quantitative	O
analysis	O
of	O
the	O
isolated	O
DNA	O
was	O
performed	O
by	O
spectrophotometry	O
using	O
the	O
NanoPhotometer	O
Pearl	O
Spectrophotometer	O
(	O
Implen	O
,	O
Germany	O
)	O
to	O
measure	O
absorbance	O
.	O

Methylation	O
status	O
and	O
mRNA	O
expression	O
of	O
genes	O
APC	O
,	O
CDKN2A	O
,	O
MGMT	O
,	O
CDH1	O
and	O
TIMP3	O
were	O
taken	O
from	O
the	O
results	O
of	O
our	O
previous	O
studies	O
[	O
]	O
.	O

HPV	O
detection	O

HPV	B-HPV_Lab_Technique
detection	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
identification	I-HPV_Lab_Technique
of	I-HPV_Lab_Technique
subtypes	I-HPV_Lab_Technique
were	I-HPV_Lab_Technique
per	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
formed	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
GenoFlow	I-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Human	I-HPV_Lab_Technique
Papillomavirus	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
Array	I-HPV_Lab_Technique
Test	I-HPV_Lab_Technique
Kits	I-HPV_Lab_Technique
[	I-HPV_Lab_Technique
FTPRO	I-HPV_Lab_Technique
]	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
DiagCor	I-HPV_Lab_Technique
Bioscience	I-HPV_Lab_Technique
Inc	I-HPV_Lab_Technique
.	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Hong	I-HPV_Lab_Technique
Kong	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
.	O

This	O
test	O
is	O
based	O
on	O
PCR	B-HPV_Lab_Technique
and	O
‘flow	O
-	O
through’	O
hybrid	O
-	O
ization	O
technology	O
allowing	O
the	O
detection	O
of	O
33	O
HPV	O
sub	O
-	O
types	O
[	O
18	O
classified	O
as	O
high	O
-	O
risk	O
and	O
15	O
as	O
low	O
-	O
risk	O
(	O
6	O
,	O
11	O
,	O
16	O
,	O
18	O
,	O
26	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
40	O
,	O
42	O
,	O
43	O
,	O
44	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
53	O
,	O
54	O
,	O
55	O
,	O
56	O
,	O

57	O
,	O
58	O
,	O
59	O
,	O
61	O
,	O
66	O
,	O
68	O
,	O
70	O
,	O
71	O
,	O
72	O
,	O
73	O
,	O
81	O
,	O
82	O
and	O
84	O
)	O
]	O
.	O

We	O

mixed	O
previously	O
isolated	O
DNA	O
with	O
HPV	B-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
Premix	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
Taq	I-HPV_Lab_Technique
Polymerase	I-HPV_Lab_Technique
provided	I-HPV_Lab_Technique
with	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
kit	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
amplified	I-HPV_Lab_Technique
it	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
a	I-HPV_Lab_Technique
Mastercycler	I-HPV_Lab_Technique
Personal	I-HPV_Lab_Technique
thermal	I-HPV_Lab_Technique
cycler	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Eppendorf	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Germany	I-HPV_Lab_Technique
)	O
according	O
to	O
the	O
manufacturer’s	O
protocol	O
.	O

There	O
-	O
after	O
,	O
we	O
performed	O
detection	O
by	O
the	O
‘flow	O
-	O
through’	O
process	O
involving	O
hybridization	O
,	O
enzyme	O
conjugation	O
and	O
colorimet	O
-	O
ric	O
detection	O
.	O

Amplification	O
controls	O
,	O
positive	O
and	O
negative	O
controls	O
,	O
and	O
also	O
hybridization	O
controls	O
were	O
performed	O
in	O
all	O
runs	O
.	O

Coloured	O
dots	O
on	O
the	O
membrane	O
indicated	O
positiv	O
-	O
ity	O
and	O
were	O
recorded	O
by	O
scanning	O
the	O
membrane	O
and	O
image	O
analysis	O
(	O
CapturePro	O
Image	O
,	O
CaptureREAD	O
3	O
.	O
1	O
.	O

;	O
DiagCor	O
Bioscience	O
Inc	O
.	O
,	O
Hong	O
Kong	O
)	O
.	O

Statistical	O
analysis	O

Significant	O
differences	O
between	O
the	O
distribution	O
of	O
methyl	O
-	O
ated	O
gene	O
promoters	O
among	O
HPV	O
[	O
+	O
]	O
and	O
[	O
]	O
groups	O
were	O
tested	O
using	O
Pearson’s	O
x2	O
test	O
.	O

The	O
Shapiro–Wilk	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
distribution	O
of	O
variables	O
.	O

Non	O
-	O
paramet	O
-	O
ric	O
variables	O
are	O
presented	O
as	O
the	O
median	O
with	O
the	O
interquar	O
-	O
tile	O
range	O
.	O

Non	O
-	O
parametric	O
variables	O
were	O
compared	O
using	O
the	O
Mann–Whitney	O
U	O
-	O
test	O
for	O
unreliable	O
variables	O
,	O
and	O
the	O
Wilcoxon	O
test	O
to	O
compare	O
variables	O
between	O
tumour	O
and	O
margin	O
.	O

Logistic	O
regression	O
modelling	O
was	O
performed	O
to	O
analyse	O
5	O
-	O
year	O
survival	O
including	O
HPV	O
status	O
,	O
age	O
,	O
grading	O
,	O
sex	O
,	O
and	O
tobacco	O
and	O
alcohol	O
consumption	O
,	O
regarding	O
these	O
as	O
both	O
independent	O
and	O
co	O
-	O
existing	O
factors	O
.	O

P	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O

The	O
statistical	O
soft	O
-	O
ware	O
STATISTICA	O
12	O
for	O
Windows	O
(	O
STATSOFT	O
,	O
USA	O
)	O
was	O
used	O
to	O
perform	O
all	O
analyses	O
.	O

